Cancer Family
Connective and Soft Tissue Neoplasm
CI-CAN-00000010Explore in graph →
Non-malignant848 active trials17 approved drugs339 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000010Explore in graph →
Clinical trials
3,877 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04278781 | AG-120 in People With IDH1 Mutant Chondrosarcoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04332874 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)((NeoScorch HN)) | recruiting | Phase 2 | 75 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548177 | Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | recruiting | Phase 2 | 33 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04082520 | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | recruiting | Phase 2 | 42 | Mayo ClinicOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04095208 | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study(CONGRATS) | completed | Phase 2 | 68 | Institut BergoniéOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04784247 | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04968106 | Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)(TORNADO) | active not recruiting | Phase 2 | 66 | Institut BergoniéOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05836571 | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | active not recruiting | Phase 2 | 66 | National Cancer Institute LAOUNKNOWN | 2 | Apr 21, 2026 | clinicaltrials |
| NCT04028063 | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 65 | University of Colorado, DenverOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT01864109 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | active not recruiting | Phase 2 | 83 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05019703 | Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04659811 | Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma | active not recruiting | Phase 2 | 35 | Nancy Ann Oberheim Bush, MDOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04189783 | Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial) | active not recruiting | Phase 2 | 113 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03601806 | Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | completed | Phase 2 | 26 | AIDS Malignancy ConsortiumNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05440786 | CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma | active not recruiting | Phase 2 | 46 | Eli Lilly and CompanyINDUSTRY | 7 | Apr 13, 2026 | clinicaltrials |
| NCT05879185 | A Study of XmAb23104 in People With Sarcoma | terminated | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05926700 | Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05661643 | The Efficacy and Safety of Temozolomide in SDH-deficient GIST(GIST) | recruiting | Phase 2 | 29 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05905887 | Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | recruiting | Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06326346 | GIST Oral Paclitaxel(Liporaxel) | recruiting | Phase 2 | 28 | Asan Medical CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06445166 | Propranolol for the Treatment of Kaposi Sarcoma in Adults | recruiting | Phase 2 | 25 | Washington University School of MedicineOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07032285 | Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas(CIRTUSARC) | recruiting | Phase 2 | 25 | Asociación Europea y Latinoamericana SELNET para la Investigación en SarcomasOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT03944304 | Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | completed | Phase 2 | 40 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04633122 | A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib | completed | Phase 2 | 108 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07096609 | Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients(LONGIST) | recruiting | Phase 1 / Phase 2 | 48 | Asan Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07007273 | Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma | recruiting | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06341712 | Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma(CabOSTar) | terminated | Phase 2 | 10 | IpsenINDUSTRY | 10 | Mar 31, 2026 | clinicaltrials |
| NCT06905132 | Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma | recruiting | Phase 2 | 40 | Medical University of South CarolinaOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07501026 | Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC)(neoSFRT-SARC) | recruiting | Phase 2 | 22 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04305548 | Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma(ISG-MCS) | recruiting | Phase 2 | 16 | Italian Sarcoma GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05152173 | Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis | completed | Phase 2 | 176 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04383119 | Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma(ISG-ARTICLE) | recruiting | Phase 2 | 100 | Italian Sarcoma GroupNETWORK | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07491783 | Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial | not yet recruiting | Phase 2 | 52 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT05046314 | A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma | completed | Phase 2 | 15 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03793361 | Phase II Study of Regorafenib as Maintenance Therapy(EREMISS) | completed | Phase 2 | 127 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | recruiting | Phase 1 / Phase 2 | 56 | Peking University People's HospitalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07477457 | A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma | recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07477548 | A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies | not yet recruiting | Phase 2 | 67 | Yonsei UniversityOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT01303094 | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma(T-DIS) | completed | Phase 2 | 53 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 23, 2026source: clinicaltrials